Note: This data is extracted from a very large study from an International Workshop on treatment related leukemias -restricted to balanced chromosome aberrations (i.e.: -5/del(5q) and -7/del(7q) not taken into account per see), published in Genes, Chromosomes and Cancer in 2002.
Clinics and pathology

Disease
Treatment related myelodysplasia (t-MDS) or acute non lymphocytic leukaemias (t-ANLL). Note The study included 79 cases; t-MDS without progression to ANLL accounted for 15%, t-MDS progressing to ANLL for 18%, t-ANLL for the remaining 67%; there was no case of acute lymphoblastic leukaemia.
Phenotype/cell stem origin
MDS cases were frequently refractory anemia with excess of blasts cases; 58% of ANLL cases were M2 ANLL.
Etiology
Frequent antracyclin exposure.
Epidemiology
21q22 rearrangements were found in 15% of t-MDS/t-ANLL; 1M to 1F sex ratio
Clinics
Age at diagnosis of the primary disease was 47 yrs (range 2-75); age at diagnosis of the t-MDS/t-ANLL was 51 yrs (11-77) and median interval was 39 mths (6-306). Primary disease was a solid tumor in 56% of cases (mainly: breast, lung, sarcoma/ PNET, colon cancer) and an hematologic malignancy in 43%. Treatment of the primary disease included radiotherapy (in 6%), chemotherapy (46%) or both (48%). 75% of patients with a 21q22 rearrangement had previously received topoisomerase II inhibitors, a higher proportion than other subgroups of treatment related leukemia, except 11q23 patients, who were 84% to have been exposed to topoisomerase II inhibitors; alkylating agents exposure was higher than in patients with t(15;17) or inv(16).
Treatment
Patients who received bone marrow transplantation had a higher median survival (31 mths).
Prognosis
Median survival was 14 mths, there was 58% of patients surviving 1 yr, 33% 2 yrs, and 18% 5 yrs., a better outcome than patients with 11q23 rearrangement, 3q21q26 rearrangement, 12p13 rearrangement, t(9;22), or t(8;16) and a worse outcome than those with t(15;17) or inv(16) treatment related leukemias. By th 21q22 group, patients with a t(8;21) had a better outcome, and those with a t(3;21) had a worse outcome.
Cytogenetics
Cytogenetics morphological
t(8;21)(q22;q22) (ETO / AML1) was found in 56% of cases, t(3;21)(q26;q22) (MDS-EVI1 / AML1 in 20 %, t(16;21)(q24;q22) (CBFA2T3 / AML1) in 5%. Rare recurrent anomalies were: t(1;21)(p36;q22), 
Additional anomalies
-7/del(7q) in 23% of cases (espacially in cases with alkylating agents exposure), +8 in 11%, -5/del(5q) rarely found; complex karyotypes in 28% of cases (more frequently than in treatment related leukemias with a 11q23 rearrangement or a t(15.17)).
Genes involved and proteins
AML1 partner
Result of the chromosomal anomaly
Hybrid gene
Description 5' AML1 -3' partner.
